Hyposmia and cognitive impairment in Gaucher disease patients and carriers

Movement Disorders

Volumn 27, Issue 4, 2012, Pages 526-532

  Mcneill, Alisdair ^a   Duran, Raquel ^b   Proukakis, Christos ^a   Bras, Jose ^b   Hughes, Derralyn ^c   Mehta, Atuhl ^c   Hardy, John ^b   Wood, Nicholas W ^b   Schapira, Anthony H V ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

Cognitive dysfunction; Genetics; Olfactory dysfunction; Parkinson's disease

Indexed keywords

GLUCOSYLCERAMIDASE;

ADULT; AGED; ARTICLE; CAUCASIAN; CLINICAL FEATURE; COGNITIVE DEFECT; COHORT ANALYSIS; CONTROLLED STUDY; DEGENERATIVE DISEASE; DISEASE COURSE; DISEASE PREDISPOSITION; ETHNIC GROUP; FEMALE; GAUCHER DISEASE; GENE MUTATION; HETEROZYGOTE; HUMAN; HYPOSMIA; JEW; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROLOGIC DISEASE; PARKINSON DISEASE; PARKINSONISM; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SMELLING DISORDER; UNIFIED PARKINSON DISEASE RATING SCALE;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; COGNITION DISORDERS; FEMALE; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; MALE; MIDDLE AGED; MUTATION; NEUROPSYCHOLOGICAL TESTS; ODORS; OLFACTION DISORDERS; SEVERITY OF ILLNESS INDEX; SMELL; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC;

EID: 84859423454     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24945     Document Type: Article

References (28)

1. Pastores GM, Hughes DA. Gaucher Disease. GeneReviews. Available at: Accessed January 30, 2012.
2. Bultron G, Kacena K, Pearson D, et al. The risk of Parkinson's disease in type I Gaucher disease. J Inherit Metab Dis 2010; 33: 167-173.
3. Rosenbloom B, Balwani M, Bronstein JM, et al. The incidence of parkinsonism in patients with type I Gaucher disease: data from the ICGG Gaucher Registry. Blood Cells Mol Dis 2011; 46: 95-102.
4. Sidransky E, Nalls MA, Aasly JO, et al. Multicentre analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med 2009; 361: 1651-1661.
5. Velayati A, Yu WH, Sidransky E. The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders. Curr Neurol Neurosci Rep 2010; 10: 190-198.
6. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain 2009; 132: 1783-1794.
7. Goker-Alpan O, Lopez G, Vithayathil J, Davis J, Hallet M, Sidransky E. The spectrum of parkinsonian manifestations associated with glucocerebrosidase mutations. Arch Neurol 2008; 65: 1353-1357.
8. Kono S, Shirakawa K, Ouchi Y, et al. Dopaminergic neuronal dysfunction associated with parkinsonism in both a Gaucher disease patient and a carrier. J Neurol Sci 2007; 252: 181-184.
9. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009; 373: 2055-2066.
10. Schapira AH, Tolosa E. Molecular and clinical prodrome of Parkinson's disease: implications for treatment. Nat Rev Neurol 2010; 6: 309-317.
11. Savica R, Rocca WA, Ahlskog JE. When does Parkinson's disease start? Arch Neurol 2010; 67: 798-801.
12. Movement Disorders Society Task Force on Rating Scales for Parkinson's Disease. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-750.
13. Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, et al. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry 2009; 80: 744-748.
14. Zadikoff C, Fox SH, Tang-Wai DF, et al. A comparison of the mini-mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord 2008; 23: 297-299.
15. Stiasny-Kolster K, Mayer G, Schäfer S, Möller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007; 22: 2386-2393.
16. Wenning GK, Tison F, Seppi K, et al. Development and validation of the Unified Multiple System Atrophy Rating Scale (UMSARS). Mov Disord 2004; 19: 1391-1402.
17. Adler CH, Hentz JG, Joyce JN, Beach T, Caviness JN. Motor impairment in normal ageing, clinically possible Parkinson's disease, and clinically probable Parkinson's disease: longitudinal evaluation of a cohort of prospective brain donors. Parkinsonism Relat Disord 2002; 9: 103-110.
18. Saunders-Pullman R, Hagenah J, Dhawan V, et al. Gaucher disease ascertained through a Parkinson's center: imaging and clinical characterization. Mov Disord 2010; 25: 1364-1372.
19. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173.
20. Ponsen MM, Stofers D, Booij J, van Eck-Smit BLF, Wolters EC, Berendse HW. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol 2004; 56; 173-181.
21. Elstein D, Guedalia J, Doniger GM, et al. Computerized cognitive testing in patients with type I Gaucher disease: effects of enzyme replacement and substrate reduction. Genet Med 2005; 7: 124-130.
22. Brockmann K, Srulijes K, Hauser AK, et al. GBA-associated PD presents with nonmotor features. Neurology 2011; 77: 276-280.
23. Williams SS, Williams J, Combrinck M, Christie S, Smith AD, McShane R. Olfactory impairment is more marked in patients with mild dementia with Lewy bodies than those with mild Alzheimer disease. J Neurol Neurosurg Psychiatry 2009; 80: 667-670.
24. Ross RW, Abbott RD, Petrovich H, et al. Association of olfactory dysfunction with incidental Lewy bodies. Mov Disord 2006; 21: 2062-2067.
25. Dalyrmple-Alford JC, MacAskill MR, Nakas CT, et al. The MoCA: well-suited screen for cognitive impairment in Parkinson disease. Neurology 2010; 75: 1717-1725.
26. Burrack MA, Hartlein J, Flores HP, Taylor-Reinwald L, Perlmutter JS, Cairns NJ. In vivo amyloid imaging in autopsy-confirmed Parkinson disease with dementia. Neurology 2010; 74: 77-84.
27. Mazzulli JR, Xu YH, Sun Y, et al. Gaucher disease glucocerebrosidase and alpha-synuclein form a bidirectional pathogenic loop in synucleinopathies. Cell 2011; 146: 37-52.
28. Alvarez-Erviti L, Rodriguez-Oroz MC, Cooper JM, et al. Chaperone-mediated autophagy markers in Parkinson disease brains. Arch Neurol 2010; 67: 1464-1472.